Schmallenberg Virus Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Supportive Care, Vector Control, Preventive Measures), By Animal Type (Cattle, Sheep, Goats), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 147.67 Million
CAGR (2026-2031)	8.04%
Fastest Growing Segment	Supportive Care
Largest Market	North America
Market Size (2031)	USD 234.85 Million

Market Overview

The Global Schmallenberg Virus Treatment Market will grow from USD 147.67 Million in 2025 to USD 234.85 Million by 2031 at a 8.04% CAGR. The Global Schmallenberg Virus Treatment Market encompasses veterinary solutions such as preventive vaccines, diagnostic tools, and supportive care therapies designed to mitigate the impact of the Orthobunyavirus on ruminant livestock. The primary drivers fueling market growth include the urgent need to prevent substantial economic losses arising from congenital malformations and stillbirths in cattle and sheep herds. Additionally, the increasing focus on livestock welfare and the necessity for robust herd health management strategies in endemic regions further stimulate the demand for effective intervention measures.

According to the National Sheep Association, in 2024, early lambing flocks in severely affected areas reported losing between 10% and 25% of lambs due to the disease, underscoring the critical need for reliable management products. Despite this demand, a significant challenge impeding market expansion is the cyclical and sporadic nature of outbreaks, which leads to unpredictable revenue streams and complicates long-term production planning for pharmaceutical manufacturers. This volatility often deters sustained investment in novel therapeutic development.

Key Market Drivers

The Increasing Incidence of Schmallenberg Virus Outbreaks in Livestock acts as a primary catalyst for market growth, creating urgent demand for diagnostic and management solutions. As the virus re-emerges in cyclical waves, the sudden surge in congenital deformities and stillbirths necessitates immediate veterinary intervention to contain spread and manage herd health. According to Agriland, February 2025, in the '22 cases of Schmallenberg virus recorded in 2024' report, the rate of confirmed Schmallenberg virus cases in Ireland increased by 2,200% in 2024 compared to the preceding year. This dramatic escalation underscores the volatility of the disease and the critical need for accessible treatment options during active infection periods. Additionally, the pathogen’s ability to affect multiple ruminant species further expands the scope of the market; according to the Irish Farmers Journal, in 2025, 12 cattle herds tested positive for the virus during the 2024 surveillance period, demonstrating the persistent threat beyond sheep populations.

Furthermore, the Economic Imperative to Mitigate Livestock Production Losses compels producers to invest in effective treatment and supportive care strategies. The financial burden associated with dystocia, veterinary assistance, and the loss of marketable offspring forces farm operators to prioritize robust health protocols to protect their margins. According to the Veterinary Record, August 2025, in the 'Survey to determine the farm-level impact of Schmallenberg virus during the 2023-2024 UK lambing season', 44 farms with confirmed infections reported significantly higher impacts on financial performance and flock welfare compared to unaffected holdings. These economic pressures drive the adoption of rigorous surveillance and response mechanisms, as minimizing the devastation on farm profitability is essential for the sustainability of ruminant production systems in endemic regions.

Download Free Sample Report

Key Market Challenges

The cyclical and sporadic nature of outbreaks presents a formidable barrier to the expansion of the Global Schmallenberg Virus Treatment Market. Unlike pathogens requiring consistent, annual intervention, this Orthobunyavirus exhibits a volatile transmission pattern dependent on vector activity and herd immunity levels, creating periods of high demand followed by extended intervals of market dormancy. This unpredictability severely hampers the ability of pharmaceutical manufacturers to forecast revenue or justify the substantial capital expenditure required for the research and production of novel therapeutics.

Consequently, stakeholders face significant risks in inventory management, often leading to stockouts during surges or wastage during lull periods. This instability is evidenced by recent volatility in infection rates. According to the National Farmers Union, in early 2024, the UK livestock sector experienced a sudden resurgence of the virus with 63 confirmed cases reported within a span of six weeks, reflecting the characteristic three-to-five-year outbreak cycle. Such erratic fluctuation deters long-term investment in advanced medical solutions, as companies prioritize stable markets over those defined by boom-and-bust dynamics.

Key Market Trends

The Adoption of Rapid Point-of-Care Diagnostic Kits is gaining momentum as livestock producers seek to bypass the logistical delays associated with centralized reference laboratories. In the absence of immediate pen-side confirmation, farmers face uncertainty during sporadic outbreaks, which hampers the rapid isolation of infected stock and complicates herd management decisions. The operational burden on current testing infrastructure illustrates this bottleneck; according to Agriland, February 2025, in the '22 cases of Schmallenberg virus recorded in 2024' report, the Department of Agriculture, Food and the Marine (DAFM) was required to process 369 cattle and 84 sheep samples to confirm viral circulation during the 2024 surveillance period. This high volume of off-site analysis drives the market preference for field-deployable tools that offer real-time pathogen detection, reducing the window between suspicion and intervention.

The Emergence of Multivalent and Combination Vaccines is being accelerated by the overlapping geographical distribution of Schmallenberg virus and other midge-borne pathogens like Bluetongue. Pharmaceutical companies are increasingly focusing on broad-spectrum formulations to provide dual protection, thereby reducing the labor and costs associated with administering multiple separate immunizations to ruminant herds. The market urgency for such integrated solutions is underscored by the sheer scale of concurrent viral threats; according to Teagasc, January 2025, in the 'Let's Talk Sheep - Bluetongue and Schmallenberg Disease' update, the Netherlands confirmed over 10,000 Bluetongue-positive premises in 2024, creating a compelling case for combined prophylactic strategies that effectively address the shared vector challenge across affected European regions.

Segmental Insights

The Supportive Care segment is currently recognized as the fastest-growing category within the Global Schmallenberg Virus Treatment Market due to the absence of specific antiviral therapies approved by regulatory bodies such as the European Medicines Agency. Since no curative drugs exist to directly neutralize the virus, veterinarians rely heavily on symptomatic management to maintain animal welfare and minimize herd losses. This necessitates the increasing utilization of hydration fluids, nutritional support, and anti-inflammatory medications to manage clinical signs, thereby securing the dominant growth position of supportive care protocols in the absence of targeted medical alternatives.

Regional Insights

North America dominates the Global Schmallenberg Virus Treatment Market, primarily driven by the concentration of leading animal health companies such as Zoetis and Merck Animal Health within the region. These industry giants leverage advanced veterinary research infrastructure to develop and manufacture essential vaccines and diagnostic tools for global distribution. Although the virus is prevalent in other continents, North America serves as the central hub for biotechnology innovation and production supply. This strategic control over product development and export capabilities firmly establishes the region’s commercial leadership in the sector.

Recent Developments

• In February 2025, veterinary practices, including Thrums Vets, announced that the supply of Schmallenberg virus vaccines was expected to return to the market in the spring of 2025. This development marked a significant turnaround for the "Global Schmallenberg Virus Treatment Market" after the period of unavailability the previous year. The resumption of supply involves key industry players like Zoetis and MSD Animal Health, who are preparing to restock their respective vaccine products, Zulvac SBV and Bovilis SBV, enabling farmers to vaccinate replacements and breeding stock ahead of the vector-active season to prevent reproductive failures and fetal malformations.
• In September 2024, the re-emergence of the Schmallenberg virus in dairy herds across parts of Europe, as reported by veterinary laboratories, drove an increased focus on the diagnostic segment of the treatment market. With clinical signs such as milk drop and fever becoming prevalent, the demand for molecular diagnostic tools capable of confirming SBV infection surged. Companies specializing in veterinary diagnostics, such as Indical Bioscience and Thermo Fisher Scientific, continued to market their real-time PCR solutions (e.g., the virotype SBV 2.0 RT-PCR Kit and VetMAX Schmallenberg Virus Kit) to facilitate early detection and differentiation from other vector-borne diseases like Bluetongue, which is crucial for appropriate herd management and containment decisions.
• In April 2024, industry reports from Farmers Weekly underscored the growing pressure on pharmaceutical companies to resume the production of Schmallenberg virus vaccines. Following a season of high losses due to the virus, veterinary professionals and farmer representatives called for manufacturers, such as Zoetis and MSD Animal Health, to recommence the supply of vaccines like Zulvac SBV and Bovilis SBV. The reports highlighted that while manufacturers had previously paused production due to fluctuating demand, the recent severe outbreaks and the cyclical nature of the disease had created a renewed and urgent market requirement for these immunological products to ensure future herd security.
• In February 2024, the Agriculture and Horticulture Development Board (AHDB) issued an advisory highlighting the critical shortage of Schmallenberg virus (SBV) vaccines in the UK market. The report confirmed that the primary vaccines, including Bovilis SBV manufactured by MSD Animal Health, were not commercially available during this period. This unavailability posed significant challenges for livestock producers facing a potential resurgence of the virus, limiting their ability to immunize cattle and sheep herds against the midge-borne disease. The advisory urged farmers to implement alternative biosecurity and management strategies to mitigate the risks of infection and subsequent congenital deformities in offspring.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis
• MSD Animal Health
• Elanco Animal Health
• Neogen Corporation
• Heska Corporation
• Phibro Animal Health
• IDT Biologika
• Phibro Animal Health
• Dechra Pharmaceuticals

By Treatment Type	By Animal Type	By Region
Supportive Care Vector Control Preventive Measures	Cattle Sheep Goats	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Schmallenberg Virus Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Schmallenberg Virus Treatment Market, By Treatment Type:

• Supportive Care
• Vector Control
• Preventive Measures

• Schmallenberg Virus Treatment Market, By Animal Type:

• Cattle
• Sheep
• Goats

• Schmallenberg Virus Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE